Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback